Esperion Secures Alkem Deal Blocking Generics Until 2040 With $156–160M 2025 Sales
Esperion secured a deal on February 17 with Alkem Laboratories to block generic versions of NEXLETOL and NEXLIZET in the US until April 19, 2040. The company reported preliminary 2025 US net product sales of $156–160 million, a 35%–38% rise over 2024 reflecting its strategy to delay generic competition.
1. Strategic Generic Delay Deals
On February 17, Esperion reached an agreement with Alkem Laboratories to prohibit the launch of generic versions of NEXLETOL and NEXLIZET in the US until April 19, 2040. This pact follows a January 11 deal with Dr. Reddy’s Laboratories and three other firms under which they also agreed to delay generic introductions until April 2040.
2. Preliminary Financial Results
Esperion reported preliminary US net product sales of $156–160 million in 2025, representing a 35%–38% increase over 2024. These gains reflect strong market uptake for NEXLETOL and NEXLIZET as the company builds revenue visibility ahead of patent expirations.
3. Vision 2040 Growth Strategy
The Vision 2040 plan aims to establish Esperion as a leader in cardiometabolic disease therapies by launching at least five products, expanding its pipeline, and forging international partnerships. Ongoing generic delay agreements underpin long-term revenue protection and support sustained investment in research and development.